We discussed drug development and approval in phase 1 of the Global Visioneering program. There is a consensus this needs to be sped up.
@iraspastor wrote that the modus operandi remains “study combinations after single interventions”, which isn’t fast enough.
Before we explore these as potential breakthroughs in phase 3, I’d like to get more clarity around why these – and other innovations – aren’t catching on? If it’s purely a matter of regulation or policy, then it might not be worth moving this forward in the Global Visioneering process. XPRIZE is not a lobby group. But if there are market failures or technological shortcomings or simply a lack of funding, that’s something we could potentially address with a prize competition.
@efoehr, @Lodder545, @Liz_Parrish, @TSeoh, and @sadiew – as pharma experts, I hope you can shed some light on this. Specifically on how to balance speed and rigor in the drug approval process, which seems to me the core of the challenge. (But please correct me if you think that’s wrong!)
If you haven’t yet, please read About Global Visioneering for a quick description of the program we launched in April.